FDA accepted NDA resubmission for Aldeyra Therapeutics, Inc., amid market reactions and speculation regarding tariff benefits for AI stocks.
1 report, 1 independent
Updated Aug 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted NDA resubmission for Aldeyra Therapeutics, Inc., amid market reactions and speculation regarding tariff benefits for AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
AbbVie (Netherlands)
company in Zwolle, Netherlands
Nothing else this week.
Related events
- FDA approval supports NDA submission in Aurora.
- Clene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- FDA policy proposal affects the operations of AI, Inc.
Coverage
Newest first; wire copies grouped- Insider MonkeyJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is among the best US stocks under $10 to invest in. Catherine Novack, an analyst at Jo